MCID: RFR010
MIFTS: 45

Refractory Anemia malady

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Refractory Anemia

Aliases & Descriptions for Refractory Anemia:

Name: Refractory Anemia 56
Refractory Anemia, Without Ringed Sideroblasts, Without Excess Blasts 69
Refractory Anemias 69
Anemia Refractory 52

Characteristics:

Orphanet epidemiological data:

56
refractory anemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 56 ORPHA98826
UMLS via Orphanet 70 C0002893
MESH via Orphanet 43 D000753
ICD10 via Orphanet 34 D46.7

Summaries for Refractory Anemia

MalaCards based summary : Refractory Anemia, also known as refractory anemia, without ringed sideroblasts, without excess blasts, is related to myeloproliferative neoplasm and hemophagocytic lymphohistiocytosis. An important gene associated with Refractory Anemia is TET2 (Tet Methylcytosine Dioxygenase 2), and among its related pathways/superpathways are PI3K-Akt signaling pathway and NF-kappaB Signaling. The drugs Cyclophosphamide and Iron have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are cellular and hematopoietic system

Related Diseases for Refractory Anemia

Diseases related to Refractory Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 115)
id Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 29.2 JAK2 MPL RUNX1
2 hemophagocytic lymphohistiocytosis 28.5 IL3 JAK2 MPL RUNX1
3 refractory anemia with excess blasts 12.2
4 refractory anemia with excess blasts in transformation 12.1
5 macrocytic anemia, refractory, due to 5q deletion, somatic 11.9
6 refractory anemia with excess blasts type 2 11.9
7 refractory anemia with excess blasts type 1 11.9
8 myelodysplastic syndrome 11.5
9 aregenerative anemia 11.2
10 anemia, sideroblastic, pyridoxine-refractory, autosomal recessive 11.1
11 acquired idiopathic sideroblastic anemia 10.9
12 anemia, sideroblastic, 3, pyridoxine-refractory 10.9
13 leukemia 10.3
14 thrombocytosis 10.2
15 regional odontodysplasia 10.2 ASXL1 TET2
16 poems syndrome 10.1 EPO TET2
17 lymphatic system cancer 10.1 ALAS2 TET2
18 long qt syndrome 10.1 EPO JAK2
19 acute liver failure 10.1 EPO JAK2
20 aarskog-scott syndrome 10.1 ALAS2 TET2
21 temporomandibular ankylosis 10.1 ASXL1 JAK2 TET2
22 myeloid leukemia 10.1
23 comt-related pain sensitivity alteration 10.1 EPO RUNX1
24 familial hyperaldosteronism 10.0 JAK2 RUNX1
25 cat-scratch disease 10.0 ALAS2 EPO
26 osteogenesis imperfecta, type viii 10.0 JAK2 MPL TET2
27 blood coagulation disease 10.0 EPO MPL
28 ocular hyperemia 10.0 JAK2 MPL
29 focal epilepsy 10.0 JAK2 MPL TET2
30 aplastic anemia 10.0
31 spondylocostal dysostosis 2 10.0 EPO JAK2 MPL
32 thrombocytopenia, congenital amegakaryocytic 10.0 IL3 MPL
33 abdominal obesity-metabolic syndrome 10.0 ASXL1 JAK2 RUNX1
34 dic in newborn 9.9 EPO IL3
35 sinusitis 9.9 IL3 JAK2
36 chronic myelomonocytic leukemia 9.9
37 middle cerebral artery infarction 9.9 IL3 RUNX1
38 pyloric stenosis, infantile hypertrophic, 4 9.9 EPO IL3 JAK2
39 queensland tick typhus 9.8 EPO IL3 JAK2
40 cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1 9.8 EPO IL3 JAK2
41 hemochromatosis 9.8
42 acute leukemia 9.8
43 neuromyelitis optica 9.8 EPO JAK2 MPL TET2
44 colorectal adenoma 9.8 ASXL1 JAK2 RUNX1 TET2
45 meningeal melanocytoma 9.8 EPO IL3
46 neuronal ceroid-lipofuscinoses 9.8 ALAS2 EPO IL3
47 acute lymphocytic leukemia 9.8 IL3 JAK2 RUNX1
48 systemic lupus erythematosus 9.7
49 mediastinitis 9.7
50 essential thrombocythemia 9.7

Graphical network of the top 20 diseases related to Refractory Anemia:



Diseases related to Refractory Anemia

Symptoms & Phenotypes for Refractory Anemia

MGI Mouse Phenotypes related to Refractory Anemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.88 EPO JAK2 MPL RUNX1 ASXL1 TET2
2 hematopoietic system MP:0005397 9.87 JAK2 MPL RUNX1 ALAS2 ASXL1 TET2
3 embryo MP:0005380 9.77 JAK2 MPL RUNX1 ALAS2 EPO
4 immune system MP:0005387 9.73 JAK2 MPL RUNX1 ASXL1 TET2 EPO
5 liver/biliary system MP:0005370 9.55 JAK2 RUNX1 ASXL1 TET2 EPO
6 mortality/aging MP:0010768 9.5 JAK2 MPL RUNX1 ALAS2 ASXL1 TET2
7 neoplasm MP:0002006 8.92 JAK2 RUNX1 ASXL1 TET2

Drugs & Therapeutics for Refractory Anemia

Drugs for Refractory Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 327)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
2
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
3
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
4
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
5
Deferasirox Approved, Investigational Phase 4 201530-41-8 5493381
6 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
7 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1
8 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
9 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1
10 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
12 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
13 Chelating Agents Phase 4,Phase 1,Phase 2
14 Iron Chelating Agents Phase 4
15 Liver Extracts Phase 4
16
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
17
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
18
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
19
Tacrolimus Approved, Investigational Phase 2, Phase 3,Phase 1 104987-11-3 445643 439492
20
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
21
Etoposide Approved Phase 2, Phase 3, Phase 1 33419-42-0 36462
22
Idarubicin Approved Phase 2, Phase 3, Phase 1 58957-92-9 42890
23
Cytarabine Approved, Investigational Phase 2, Phase 3, Phase 1 147-94-4 6253
24
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
25
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 4053 460612
26
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
27
Metoclopramide Approved, Investigational Phase 3 364-62-5 4168
28
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
29
rituximab Approved Phase 2, Phase 3, Phase 1 174722-31-7 10201696
30
Prednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 50-24-8 5755
31
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
32
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3, Phase 1 83-43-2 6741
33
Azacitidine Approved, Investigational Phase 3,Phase 2,Phase 1 320-67-2 9444
34
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
35
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
36
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
37
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
38
Amsacrine Approved Phase 3 51264-14-3 2179
39
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
40
Trimetrexate Approved, Investigational Phase 3 52128-35-5 5583
41
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
42
Vidarabine Approved Phase 3,Phase 2,Phase 1 24356-66-9 32326 21704
43
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
44
alemtuzumab Approved, Investigational Phase 2, Phase 3, Phase 1 216503-57-0
45
Lenalidomide Approved Phase 3,Phase 1,Phase 2 191732-72-6 216326
46
Clofarabine Approved, Investigational Phase 2, Phase 3 123318-82-1 119182
47
Benzocaine Approved Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
48
Thioguanine Approved Phase 3 154-42-7 2723601
49
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
50
Asparaginase Approved Phase 3 9015-68-3

Interventional clinical trials:

(show top 50) (show all 312)
id Name Status NCT ID Phase
1 Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload Completed NCT00481143 Phase 4
2 An Epidemiological Study to Assess Iron Overload Using MRI in Patients With Transfusional Siderosis (TIMES Study) Completed NCT01736540 Phase 4
3 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
4 Bowel Preparation and Prokinetics in Capsule Endoscopy Unknown status NCT00275184 Phase 3
5 Treatment of Adults Aged Up to 60 Years With De Novo Acute Myeloblastic Leukaemia,Secondary AML, or RAEB-T Unknown status NCT00209833 Phase 2, Phase 3
6 Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes Unknown status NCT01196715 Phase 3
7 Erythropoietin (EPO) and Granulocyte-Colony Stimulating Factor (G-CSF) for Low-Risk Myelodysplastic Syndromes (MDS) Unknown status NCT00234143 Phase 2, Phase 3
8 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia Unknown status NCT00002926 Phase 3
9 Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00003602 Phase 3
10 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3
11 Epoetin Alfa or Epoetin Beta With or Without Iron Infusion in Treating Anemia in Patients With Cancer Unknown status NCT00482716 Phase 3
12 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3
13 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3
14 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3
15 Antithymocyte Globulin and Cyclosporine in Treating Patients With Myelodysplastic Syndrome Completed NCT00004208 Phase 3
16 Erythropoietin (EPO)+/- Filgrastim (G-CSF) vs. Supportive Therapy Alone for Patients With Myelodysplastic Syndromes Completed NCT00003138 Phase 3
17 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3
18 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
19 Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma Completed NCT00003187 Phase 2, Phase 3
20 S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia Completed NCT00005866 Phase 3
21 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia Completed NCT00003436 Phase 3
22 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3
23 Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation Completed NCT00004255 Phase 2, Phase 3
24 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3
25 Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer Completed NCT00060398 Phase 3
26 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3
27 Impact of Erythropoietin Treatment Versus Placebo on Quality-of-life in Patients With Advanced Prostate Cancer. Completed NCT00364455 Phase 3
28 IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose Completed NCT02130063 Phase 3
29 Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3
30 Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia Completed NCT01134432 Phase 3
31 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
32 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
33 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
34 Safety and Effectiveness of Two Blood Transfusion Strategies in Surgical Patients With Cardiovascular Disease Completed NCT00071032 Phase 3
35 An Open, Prospective, Multicenter Study of Trimetrexate With Leucovorin Rescue for AIDS Patients With Pneumocystis Carinii Pneumonia (PCP) and Serious Intolerance to Approved Therapies Completed NCT00000714 Phase 3
36 Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia Completed NCT00281892 Phase 3
37 Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anaemia Due to Angiodysplasias Recruiting NCT02384122 Phase 2, Phase 3
38 Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA Recruiting NCT02562443 Phase 3
39 G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT Recruiting NCT02744742 Phase 2, Phase 3
40 Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT Recruiting NCT02850822 Phase 2, Phase 3
41 ImmuniCell® in Patients With Advanced Cancers Recruiting NCT02459067 Phase 2, Phase 3
42 A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Recruiting NCT02631070 Phase 3
43 Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Recruiting NCT02598661 Phase 3
44 Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine Active, not recruiting NCT01928537 Phase 3
45 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
46 Study of Romiplostim(AMG531) in Subjects With Aplastic Anemia Active, not recruiting NCT02773290 Phase 2, Phase 3
47 A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q Active, not recruiting NCT01029262 Phase 3
48 Impact of Pre-pregnancy Micronutrient Supplementation on Maternal and Child Outcomes Active, not recruiting NCT01665378 Phase 3
49 Ketamine as an Adjuvant Therapy for Acute Vaso Occlusive Crisis in Pediatric Patients With Sickle Cell Disease Not yet recruiting NCT02801292 Phase 3
50 A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia. Terminated NCT00363025 Phase 3

Search NIH Clinical Center for Refractory Anemia

Genetic Tests for Refractory Anemia

Anatomical Context for Refractory Anemia

MalaCards organs/tissues related to Refractory Anemia:

39
Bone, Bone Marrow, Myeloid, T Cells, Neutrophil, Liver, Breast

Publications for Refractory Anemia

Articles related to Refractory Anemia:

(show top 50) (show all 398)
id Title Authors Year
1
Acquired elliptocytosis in the setting of a refractory anemia with excess blasts and del(20q). ( 28092889 )
2016
2
Management of differentiation syndrome in an elderly patient with acute promyelocytic leukemia who subsequently developed refractory anemia with ring sideroblasts. ( 27073113 )
2016
3
Low Dose Cytosine Arabinoside and Azacitidine Combination in Elderly Patients with Acute Myeloid Leukemia and Refractory Anemia with Excess Blasts (MDS-RAEB2). ( 26855506 )
2016
4
"Irony" of managing refractory anemia with transfusional support in hemophagocytic lymphohistiocytosis. ( 27102761 )
2016
5
Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing. ( 26874914 )
2016
6
Vascular events and risk factors for thrombosis in refractory anemia with ring sideroblasts and thrombocytosis. ( 27479179 )
2016
7
Survey of experts on therapeutic policies and proposals for the optimal timing for allogeneic peripheral blood stem cell transplantation in transfusion-dependent patients with myelodysplastic syndrome-refractory anemia. ( 27104191 )
2016
8
Treatment of Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis with Lenalidomide in a Patient Testing Negative for 5q Deletion and JAK2 V617F and MPL W515K/L Mutations. ( 27994837 )
2016
9
Erythroblast morphology in refractory anemia with ring sideroblasts and thrombocytosis. ( 27301073 )
2016
10
Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and DNMT3A in refractory anemia with ring sideroblasts (RARS). ( 27771989 )
2016
11
Imetelstat therapy in refractory anemia with ring sideroblasts with or without thrombocytosis. ( 26967822 )
2016
12
Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. ( 27558206 )
2016
13
Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study. ( 27107658 )
2016
14
Abnormalities in the T Cell Receptor VI' Repertoire and Foxp3 Expression in Refractory Anemia with Ringed Sideroblasts. ( 26154600 )
2015
15
Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation. ( 25963624 )
2015
16
Regaining the response to erythropoietin following azacitidine in chronic myelomonocytic leukemia previously evolved from refractory anemia. ( 26457287 )
2015
17
Myeloid Sarcoma of the Bladder in the Setting of Refractory Anemia with Excess Blasts-2 (RAEB-2). ( 26665895 )
2015
18
Dramatic improvement of refractory anemia caused by mechanical hemolysis in a patient with hypertrophic obstructive cardiomyopathy using dual-chamber pacing. ( 26336568 )
2015
19
Molecular and phenotypic heterogeneity of refractory anemia with ring sideroblasts associated with marked thrombocytosis. ( 25926061 )
2015
20
Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG). ( 26400023 )
2015
21
Biosimilar epoetin I+ is as effective as originator epoetin-I+ plus liposomal iron (SideralAr), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach. ( 26171179 )
2015
22
Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T). ( 25899435 )
2015
23
Deregulation of genes related to iron and mitochondrial metabolism in refractory anemia with ring sideroblasts. ( 25955609 )
2015
24
Severe Refractory Anemia in Primary Intestinal Lymphangiectasia. A Case Report. ( 26405709 )
2015
25
Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts. ( 25709892 )
2015
26
An MPL W515L mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis: A case report. ( 25621045 )
2015
27
Metastatic Choriocarcinoma of the Small Intestine Presenting as Refractory Anemia and Melena. ( 26157939 )
2015
28
A Case of Refractory Anemia with Excess Blast-2 with Sole Trisomy 13. ( 26299091 )
2015
29
Deferasirox in a refractory anemia after other treatment options: case report and literature review. ( 26185629 )
2015
30
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations. ( 25527566 )
2015
31
Isolated trisomy 13 in refractory anemia with excess blasts: report of two cases and a brief literature review of this possible association. ( 26133721 )
2015
32
Refractory anemia in systemic sclerosis: myelodisplastic syndrome. ( 27708945 )
2015
33
A yet unreported der(11)t(6;11)(p21;q21) included in a complex karyotype of a refractory anemia with ring sideroblasts and poor prognosis. ( 24439112 )
2014
34
Histopathological evaluation of the bone marrow in refractory anemia with ring sideroblasts and thrombocytosis associated to the JAK2-V617F mutation. ( 24624040 )
2014
35
Refractory anemia with ring sideroblasts associated with thrombocytosis (RARS-T). ( 24575445 )
2014
36
Proteome changes in the plasma of myelodysplastic syndrome patients with refractory anemia with excess blasts subtype 2. ( 24958999 )
2014
37
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts. ( 24476767 )
2014
38
The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. ( 23070040 )
2013
39
A case of refractory anemia with ring sideroblasts and associated thrombocytosis. ( 23844433 )
2013
40
Refractory anemia with ring sideroblasts associated with marked thrombocytosis complicated by massive splenomegaly treated with lenalidomide resulting in resolution of splenomegaly but severe and prolonged pancytopenia. ( 23653870 )
2013
41
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms. ( 22929973 )
2013
42
Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome. ( 23826588 )
2013
43
Refractory anemia with ring sideroblasts. ( 24507814 )
2013
44
Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts. ( 23065512 )
2013
45
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis. ( 23252419 )
2013
46
Correlation between dysplastic lineage and type of cytopenia in myelodysplastic syndromes patients with refractory anemia according to the FAB classification. ( 23897263 )
2013
47
Plasma proteome changes associated with refractory anemia and refractory anemia with ringed sideroblasts in patients with myelodysplastic syndrome. ( 23566303 )
2013
48
Pathogenetic role of ETV6 fusion gene in leukemic transformation of myelodysplastic syndrome refractory anemia with excess blasts-1 with a new, rare translocation t(11;19)(q24.3;q13.12) and insertion ins(6;12)(p22.3p13). ( 23772667 )
2013
49
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( 23515411 )
2013
50
Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases. ( 24399021 )
2013

Variations for Refractory Anemia

Expression for Refractory Anemia

Search GEO for disease gene expression data for Refractory Anemia.

Pathways for Refractory Anemia

GO Terms for Refractory Anemia

Biological processes related to Refractory Anemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 covalent chromatin modification GO:0016569 9.63 ASXL1 JAK2 TET2
2 cytokine-mediated signaling pathway GO:0019221 9.54 IL3 JAK2 MPL
3 hemopoiesis GO:0030097 9.5 ASXL1 RUNX1 TET2
4 positive regulation of DNA replication GO:0045740 9.43 EPO IL3
5 homeostasis of number of cells GO:0048872 9.4 ASXL1 TET2
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.33 EPO IL3 JAK2
7 hemoglobin biosynthetic process GO:0042541 9.26 ALAS2 EPO
8 erythrocyte differentiation GO:0030218 9.13 ALAS2 EPO JAK2
9 positive regulation of tyrosine phosphorylation of Stat5 protein GO:0042523 8.8 EPO IL3 JAK2

Sources for Refractory Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....